Biosimilars

Brain Cancer

Neoadjuvant HER2+

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immunotherapy in GU Cancers

Immunotherapy in Lung Cancer

Immunotherapy in Melanoma

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Oncology Nursing News

Pediatric Oncology

Special Reports in Personalized Cancer Care

Precision Medicine in Oncology®

Sarcomas/TGCT

Supportive Care

MammaPrint high 2 HR-positive/HER2-negative early-stage breast cancer exhibited a heightened immune active state.

MammaPrint High 2 Indication Could Be Predictive Biomarker for Immunotherapy in HR+/HER2– Early Breast Cancer

Linvoseltamab elicited outcomes equivalent to those seen with teclistamab in patients with triple-class exposed relapsed/refractory multiple myeloma.

Linvoseltamab Generates Efficacy Similar to That Seen With Teclistamab in R/R Myeloma

Dostarlimab plus carboplatin and paclitaxel improved PFS and OS in dMMR/MSI-H primary advanced or recurrent endometrial cancer. 

Dostarlimab With Carboplatin/Paclitaxel Shows Survival Benefits in dMMR/MSI-H Endometrial Cancer

Pembrolizumab and platinum-based therapy elicited safe and efficacious outcomes in penile squamous cell carcinoma.

Pembrolizumab With Platinum-Based Therapy is Safe and Efficacious in PSCC

News

OncClub

All Oncology News

Pipeline Report

Media

Insights

MedNews Week

Medical World News

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

The Talk

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

PER Events

Scientific Interchanges

State of the Science Summit / IPC

Webinars

Partners

Publications

Oncology Live®

Oncology Fellows

Supplements and Featured Publications

All Publications

CME/CE

Resources

Interactive Tools

Learning Modules

Presentations

Biomarker Consortium

Subscribe

Articles

Data from a large prospective cohort study reveal that a polygenic risk score has the potential to predict survival outcomes in patients with breast cancer. 

Study Shows Polygenic Risk Score (PGS) Could Predict Breast Cancer Survival Outcomes

Benjamin L. Maughan, MD, PharmD, dives into key studies in RCC regarding biomarkers and first-line treatments presented at the 2024 ASCO Annual Meeting

Notable RCC Data Presented at ASCO May Shed Light on Key Biomarkers and Combination Approaches

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

CancerNetwork.com

CGTlive.com

CureToday.com

OncNursingNews.com

TargetedOnc.com

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

Twitter

LinkedIn

Youtube

Spotlight

In-person and virtual events just for HCPs

Specialty

1rem

primary

View

The Role of Tyrosine Kinase Inhibitors in Unresectable Hepatocellular Carcinoma

Clinical

Video Series

Real-World Evidence on Second-Line Therapy Selection and Outcomes

Videos

Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, discuss the role of tyrosine kinase inhibitors in unresectable hepatocellular carcinoma, second-line treatment options, and recent clinical trials.

Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, discuss driving forces for the development of hepatocellular carcinoma, including different types of viral hepatitis and non-alcoholic steatohepatitis.

Examining the Role of Liver Function in HCC

The key opinion leaders discuss staging systems they use in clinical practice and their effectiveness in creating treatment algorithms, particularly with respect to Child-Pugh scores.

HCC Staging: Improving Treatment Strategies

Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, review locoregional therapies for hepatocellular carcinoma, including transarterial chemoembolization (TACE) and radioembolization.

Locoregional Therapies for Intermediate-Stage HCC

Medical experts discuss the LAUNCH study, EMERALD-1, and LEAP-012 trials, providing updates on the progress and findings that influence the treatment paradigm for hepatocellular carcinoma.

HCC Trials: Insights from the LAUNCH, EMERALD-1, and LEAP-012 Trials

The panelists examine the effectiveness of transarterial chemoembolization (TACE) in treating hepatocellular carcinoma in patients with intermediate-stage disease and discuss the future prospects for these patients. 

Emerging Therapies in Intermediate-Stage HCC 

Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, provide an overview of the IMbrave150 study, the LEAP-002 trial, and the HIMALAYA trial, discussing how these trials have changed the treatment landscape for hepatocellular carcinoma. 

Updates from IMbrave150, LEAP-002, and HIMALAYA Trials 

The panelists discuss factors that may preclude patients from receiving certain therapies, such as cardiovascular comorbidities, which may pose an immediate threat to the patient's life.

Comorbidity Considerations for HCC Treatment

Medical experts discuss the selection of second-line treatments for patients who experience disease progression while on first-line therapy, highlighting the potential for deterioration in performance status and liver function.

The Evolving Landscape of Second-Line Therapies in HCC Management

Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, discuss a novel therapy that, although not practice-changing, provides an additional treatment option for patients with hepatocellular carcinoma. 

Additional Second-Line Treatments for HCC

Medical experts discuss how the time to progression, progression patterns, and real-world data influence the provider's choice of treatment for patients with hepatocellular carcinoma. 

Real-World Evidence on Second-Line Therapy Selection and Outcomes 

In their concluding remarks, Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, express their hopes for future advancements in hepatocellular carcinoma (HCC) treatment, including cellular-based therapies, antibody-drug conjugates, and an increased focus on neoadjuvant studies.

Pioneering Breakthroughs in HCC Treatment

Real-World Evidence on Second-Line Therapy Selection and Outcomes

EP: 1.Examining the Role of Liver Function in HCC

EP: 2.HCC Staging: Improving Treatment Strategies

EP: 3.Locoregional Therapies for Intermediate-Stage HCC

EP: 4.HCC Trials: Insights from the LAUNCH, EMERALD-1, and LEAP-012 Trials

EP: 5.Emerging Therapies in Intermediate-Stage HCC

EP: 6.Updates from IMbrave150, LEAP-002, and HIMALAYA Trials

EP: 7.Comorbidity Considerations for HCC Treatment

EP: 8.The Evolving Landscape of Second-Line Therapies in HCC Management

EP: 9.Additional Second-Line Treatments for HCC

EP: 10.Real-World Evidence on Second-Line Therapy Selection and Outcomes

EP: 11.Pioneering Breakthroughs in HCC Treatment

Latest Conference Coverage